Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shichao Zhou

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Therapeutic Advances in Medical Oncology|June 27, 2025
Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysisLinjing Zhou, Yuwei Li, Le Wang, et al.
Thoracic Cancer|November 21, 2025
Treatment-Related Adverse Events of Antibody-Drug Conjugate Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-AnalysisYuwei Li, Linjing Zhou, Sini Li, et al.
International Journal of Colorectal Disease|January 11, 2019
Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patientsLili Wang, Shichao Zhou, Wenying Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2025
Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastasesQian Zhang, Yehao Yang, Mingying Xie, et al.
American Journal of Physiology. Heart and Circulatory Physiology|December 1, 2018
P209L mutation in Bag3 does not cause cardiomyopathy in miceXi Fang, Julius Bogomolovas, Paul Shichao Zhou, et al.
Cell Death and Differentiation|September 28, 2022
Transient targeting of BIM-dependent adaptive MCL1 preservation enhances tumor response to molecular therapeutics in non-small cell lung cancerKaixuan Shi, Haijiao Lu, Zhenfeng Zhang, et al.
Cancer Research|July 20, 2022
Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian CancerLin Cheng, Shichao Zhou, Shaoqing Zhou, et al.
Cell Death & Disease|November 28, 2024
YY1 downregulation underlies therapeutic response to molecular targeted agentsShichao Zhou, Jingyu Zang, Mei-Chun Cai, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Therapeutic Advances in Medical Oncology|June 27, 2025
Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysisLinjing Zhou, Yuwei Li, Le Wang, et al.
Thoracic Cancer|November 21, 2025
Treatment-Related Adverse Events of Antibody-Drug Conjugate Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-AnalysisYuwei Li, Linjing Zhou, Sini Li, et al.
International Journal of Colorectal Disease|January 11, 2019
Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patientsLili Wang, Shichao Zhou, Wenying Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2025
Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastasesQian Zhang, Yehao Yang, Mingying Xie, et al.
American Journal of Physiology. Heart and Circulatory Physiology|December 1, 2018
P209L mutation in Bag3 does not cause cardiomyopathy in miceXi Fang, Julius Bogomolovas, Paul Shichao Zhou, et al.
Cell Death and Differentiation|September 28, 2022
Transient targeting of BIM-dependent adaptive MCL1 preservation enhances tumor response to molecular therapeutics in non-small cell lung cancerKaixuan Shi, Haijiao Lu, Zhenfeng Zhang, et al.
Cancer Research|July 20, 2022
Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian CancerLin Cheng, Shichao Zhou, Shaoqing Zhou, et al.
Cell Death & Disease|November 28, 2024
YY1 downregulation underlies therapeutic response to molecular targeted agentsShichao Zhou, Jingyu Zang, Mei-Chun Cai, et al.
Pageof 2